Browse > Article

The Relationship between Hyperhomocysteinemia and C677T MTHFR Gene Polymorphism in Patients with Ischemic Stroke  

Kim, Sang-Beom (Department of Neurology, Pochon CHA University College of Medicine)
Lee, Gue-Yong (Department of Neurology, Pochon CHA University College of Medicine)
Seo, Jung-Ho (Department of Neurology, Pochon CHA University College of Medicine)
Kim, Hyun-Jo (Department of Neurology, Pochon CHA University College of Medicine)
Kim, Ok-Joon (Department of Neurology, Pochon CHA University College of Medicine)
Jung, Bo-Woo (Department of Neurology, Pochon CHA University College of Medicine)
Oh, Do-Yeun (Institute for Clinical Research Pochon CHA University College of Medicine)
Kim, Nam-Keun (Institute for Clinical Research Pochon CHA University College of Medicine)
Kim, Sun-Hee (Institute for Clinical Research Pochon CHA University College of Medicine)
Chung, Kyung-Cheon (Department of Neurology, College of Medicine, Kyung Hee University)
Choi, Byung-Ok (Department of Neurology, Pochon CHA University College of Medicine)
Publication Information
Journal of the Korean neurological association / v.20, no.4, 2002 , pp. 346-352 More about this Journal
Abstract
Background : Hyperhomocysteinemia is an independent risk factor for cerebrovascular disease. MTHFR 677TT genotype can induce hyperhomocysteinemia. However, the association between this 677TT genotype and ischemic stroke still remains controversial. This study was undertaken to determine whether MTHFR 677TT genotype was associated with certain subtype of ischemic stroke. Methods : The case group consisted of 129 patients with ischemic stroke and the control group consisted of 157 healthy individuals. We checked their fasting plasma homocysteine levels and analyzed the C677T mutation in the MTHFR gene. The relative risk of MTHFR 677TT genotype was assessed by odds ratios using multivariate logistic regression. Results : Homocysteine levels in plasma were significantly higher in ischemic stroke patients (10.386.44 mol/L) than in controls (8.002.40) (P<0.05). In small-artery disease (11.366.01), the same result was found (P<0.05). On the other hand, the prevalence of the homozygote mutation was not significantly higher in ischemic stroke patients (20.2%) than in controls (13.4%) (adjusted OR 1.39, 95% CI 0.65 to 2.96). The adjusted OR and 95% CI was 2.59 (1.08 to 6.25) for the TT genotype in patients with small-artery disease compared to controls. The 677TT genotype was increased in small-artery disease compared to large-artery disease (adjusted OR 7.60, 95% CI 1.66 to 34.77). Conclusions : Our findings suggest that the homozygous C677T mutation in the MTHFR gene is a risk predictor in the subtype of ischemic stroke, such as small-artery disease.
Keywords
MTHFR; Homocysteine; Small-artery disease; Large-artery disease; Risk factor;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 McCully KS, McCully M, Stacey M. The heart revolution: the B vitamin breakthrough that lowers homocys teine, cuts your risk of heart disease, and protects your health. 1st ed. New York: HarperCollins. 1999;1-234
2 McCully KS. Vascular pathology of homocysteinemia:implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-128   PUBMED
3 Goyette P, Frosst P, Rosenblatt DS, Rozen R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Am J Hum Genet 1995;56(5):1052-1059.   PUBMED
4 Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 1996;98(1):24-29   DOI   ScienceOn
5 Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996;98:5-7   DOI   ScienceOn
6 Jakubowski H, Zhang L, Bardeguez A, Aviv A. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ Res 2000;87(1):45-51   DOI   PUBMED   ScienceOn
7 Meiklejohn DJ, Vickers MA, Dijkhuisen R, Greaves M. Plasma homocysteine concentrations in the acute and convalescent periods of atherothrombotic stroke. Stroke 2001;32(1):57-62   DOI   PUBMED   ScienceOn
8 Aronow WS, Ahn C, Gutstein H. Increased plasma homocysteine is an independent predictor of new atherothrombotic brain infarction in older persons. Am J Cardiol 2000;86(5):585-586   DOI   ScienceOn
9 Yoo JH, Choi GD, Kang SS. Pathogenicity of thermolabile methylenetetrahydrofolate reductase for vascular dementia. Arterioscler Thromb Vasc Biol 2000;20(8):1921-1925.   DOI   PUBMED   ScienceOn
10 Chango A, Boisson F, Barbe F, Quilliot D, Droesch S,Pfister M, et al. The effect of 677C \longrightarrowT and 1298A \longrightarrow Cmutations on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase activity in healthy subjects. Br J Nutr 2000;83(6):593-596   DOI   ScienceOn
11 Soriente L, Coppola A, Madonna P, Cerbone AM, Di Minno G, Orefice G, et al. Homozygous C677T mutation of the 5,10 methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in Italian patients with a history of early-onset ischemic stroke. Stroke 1998;29(4):869-871.   DOI   PUBMED   ScienceOn
12 Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF,Selhub J, D’Agostino RB, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons:the Framingham Study. Ann Intern Med 1999;131(5):352-355   DOI   PUBMED   ScienceOn
13 Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996 ;94(10):2410-2416   DOI   PUBMED   ScienceOn
14 Christensen B, Frosst P, Lussier-Cacan S, Selhub J, Goyette P, Rosenblatt DS, et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol 1997;17(3):569-573.   DOI   PUBMED   ScienceOn
15 Fassbender K, Mielke O, Bertsch T, Nafe B, Froschen S, Hennerici M. Homocysteine in cerebral macroangiography and microangiopathy. Lancet 1999;353(9164):1586-1587   DOI   PUBMED   ScienceOn
16 Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998;98(23):2520-2526   DOI   PUBMED   ScienceOn
17 Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91(1):308-318.   DOI   ScienceOn
18 Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E,Staples N, Baker RI. Association between high homocyst(e)ine and ischemic stroke due to large- and smallartery disease but not other etiologic subtypes of ischemic stroke. Stroke 2000;31(5):1069-1075   DOI   PUBMED   ScienceOn
19 Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-2698.   DOI   ScienceOn
20 D’Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997;90(1):1-11
21 Evers S, Koch HG, Grotemeyer KH, Lange B, Deufel T,Ringelstein EB. Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia.Arch Neurol 1997;54(10):1276-1282   DOI   PUBMED   ScienceOn
22 Pezzini A, Del Zotto E, Archetti S, Negrini R, Bani P,Albertini A, et al. Plasma homocysteine concentration, C677T MTHFR genotype, and 844ins68bp CBS genotype in young adults with spontaneous cervical artery dissection and atherothrombotic stroke. Stroke 2002;33(3):664-669   DOI   ScienceOn
23 Clarke R, Frost C, Leroy V, Collins R, for the Homocysteine Lowering Trialists Collaboration. Lowering blood homocysteine with folic acid based supplements: metaanalysis of randomised trials. BMJ 1998;316:894-898   DOI   ScienceOn
24 Markus HS, Ali N, Swaminathan R, Sankaralingam A, Molloy J, Powell J. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke1997;28(9):1739-1743   DOI   PUBMED   ScienceOn
25 Jeong DS, Song IU, Cho SG, Sung GB, Park HK, Chang SK, et al. A pilot study on total plasma homocysteine level of patients with cerebral infarction. J Korean Neurol Assoc 1999;17(1):26-31
26 Chadefaux B, Coude M, Hamet M, Aupetit J, Kamoun P.Rapid determination of total homocysteine in plasma. Clin Chem 1989;35:2002
27 Nappo F, De Rosa N, Marfella R, De Lucia D, Ingrosso D,Perna AF, et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999;281(22):2113-2118   DOI   ScienceOn
28 Press RD, Beamer N, Evans A, DeLoughery TG, Coull BM. Role of a common mutation in the homocysteine regulatory enzyme methylenetetrahydrofolate reductase in ischemic stroke. Diagn Mol Pathol 1999;8(1):54-58   DOI   ScienceOn
29 Ueland PM, Helland S, Broch OJ, Schance JS. Homocysteine in tissues of the mouse. J Biol Chem 1984;259:2360-2364   PUBMED
30 Clarke R, Daly L, Robinson K, Naughten E, Cahalane S,Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324(17):1149-1155   DOI   PUBMED   ScienceOn
31 Morita H, Kurihara H, Tsubaki S, Sugiyama T, Hamada C, Kurihara Y, et al. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. Arterioscler Thromb Vasc Biol 1998;18(9):1465-1469   DOI   PUBMED   ScienceOn
32 Diaz-Arrastia R. Homocysteine and neurologic disease. Arch Neurol 2000;57(10):1422-1427   DOI   PUBMED   ScienceOn
33 Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation 1999;99(9):1156-1160.   DOI   PUBMED   ScienceOn
34 Kang SS, Wong PW, Susmano A, Sora J, Norusis M,Ruggie N. Thermolabile methylenetetrahydrofolate reductase:an inherited risk factor for coronary artery disease. Am J Hum Genet 1991;48(3):536-545   PUBMED
35 Malinow MR, Duell PB, Hess DL, Anderson PH, Kruger WD, Phillipson BE, et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998;338(15):1009-1015.   DOI   ScienceOn
36 Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340(19):1449-1454   DOI   ScienceOn